Corvus Pharmaceuticals, Inc. Share Price

Stocks

CRVS

US2210151005

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 14:57:24 21/07/2026 BST 5-day change 1st Jan Change
14.42 USD +2.27% Intraday chart for Corvus Pharmaceuticals, Inc. -5.41% +83.90%

Valuation: Corvus Pharmaceuticals, Inc.

Market Cap 1.19B 1.04B 961M 883M 1.67B 114B 1.69B 11.49B 4.5B 55.94B 4.45B 4.36B 193B P/E 2026 *
-20.7x
P/E 2027 * -16.6x
Enterprise Value 983M 861M 796M 732M 1.38B 94.77B 1.4B 9.52B 3.73B 46.37B 3.69B 3.61B 160B EV / Sales 2026 *
-
EV / Sales 2027 * 158x
Free-Float
92.6%
Yield 2026 *
-
Yield 2027 * -
1 day+2.27%
1 week-5.41%
Current month-5.22%
1 month+12.74%
3 months-17.39%
6 months-36.07%
Current year+83.90%
1 week 13.9
Extreme 13.9
15.29
1 month 12.08
Extreme 12.085
16.47
Current year 6.39
Extreme 6.39
26.95
1 year 3.96
Extreme 3.96
26.95
3 years 1.05
Extreme 1.05
26.95
5 years 0.61
Extreme 0.607
26.95
10 years 0.61
Extreme 0.607
26.95
Manager TitleAgeSince
Chief Executive Officer 75 31/01/2014
Director of Finance/CFO 71 31/10/2014
Chief Operating Officer - 31/12/2020
Director TitleAgeSince
Director/Board Member 66 31/10/2014
Chairman 75 26/01/2014
Director/Board Member 64 02/01/2017
Date Insider Type Main position Quantity % Market Cap.
11/06/26 Buy

Director

36,700 0.0436%
11/06/26 Free

Director

15,000 0.0178%
11/06/26 Free

Director

15,000 0.0178%
Change 5-day change 1-year change 3-year change Capi.($)
+2.27%-5.41%+218.20%+413.97% 1.19B
-0.44%-4.12%-0.57%+13.75% 48.71B
+1.07%-2.15%+371.08%+576.09% 38.35B
+2.80%+4.12%+9.34%+61.62% 34.53B
-0.12%-3.27%+26.46%-11.93% 34.03B
-1.82%-1.43%+0.52%+31.85% 26.77B
+0.66%-5.34% - - 15.64B
+1.79%-0.22%+73.20%+118.11% 15.08B
-2.42%+0.55%+12.67%+13.55% 14.18B
+0.05%-2.46%+17.33%-33.38% 12.73B
Average +0.37%-1.43%+80.92%+131.52% 24.12B
Weighted average by Cap. +0.28%-1.45%+76.27%+121.37%

Financials

2026 *2027 *
Net sales - 5.68M 4.98M 4.6M 4.23M 7.99M 548M 8.12M 55.05M 21.58M 268M 21.34M 20.87M 924M
Net income -64M -56.1M -51.86M -47.69M -89.99M -6.17B -91.43M -620M -243M -3.02B -240M -235M -10.4B -82.02M -71.89M -66.45M -61.12M -115M -7.91B -117M -795M -311M -3.87B -308M -301M -13.33B
Net Debt -203M -178M -164M -151M -285M -19.56B -290M -1.97B -770M -9.57B -762M -745M -32.98B -290M -254M -235M -216M -407M -27.92B -414M -2.81B -1.1B -13.66B -1.09B -1.06B -47.07B
Logo Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
Employees
37
Date Price Change Volume
21/07/26 US$14.16 +0.43% 22,841
20/07/26 US$14.10 -5.37% 656,968
17/07/26 US$14.90 +4.41% 780,732
16/07/26 US$14.27 -4.36% 1,257,063
15/07/26 US$14.92 -0.33% 878,138
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
14.10USD
Average target price
33.33USD
Spread / Average Target
+136.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRVS Stock